Elcombe PhD Scholarship in Breast Cancer Research

Basil Hetzel Institute, The Queen Elizabeth Hospital, and Adelaide Medical School, University of Adelaide.

The Elcombe PhD scholarship (equivalent in value to an Australian Postgraduate Award) will be awarded to an outstanding applicant interested in pursuing PhD studies in testing novel inhibitors for breast cancer treatment, using both in vitro screening and mouse models of breast cancer. These studies will be undertaken under the supervision and mentorship of Dr Amanda Townsend MBBS FRACP, Medical Oncology, The Queen Elizabeth Hospital; Adelaide Medical School, Dr Jennifer Hardingham PhD, Molecular Oncology Research Unit, Basil Hetzel Institute; Adelaide Medical School, and Professor Andrea Yool PhD, Professor of Physiology, Adelaide Medical School and Director, Aquaporin Physiology and Drug Discovery Research Program, University of Adelaide. The scholarship is made possible by a kind donation from Dr Margaret Elcombe via The Hospital Research Foundation and is gratefully  acknowledged.

Project title: Pre-clinical investigation of the efficacy of novel aquaporin 1 inhibitors in  preventing growth and metastasis of breast cancer

Aquaporin 1 (AQP 1) is a water channel protein involved in cellular water and ion flux, and is implicated in migration, angiogenesis and metastasis in cancer. We have found that several aquaporin inhibitors that are effective in vitro at reducing migration and invasion of colon  cancer cells and preventing angiogenesis (tumour blood vessel formation). We aim to  investigate the efficacy of these drugs in inhibiting angiogenesis in vitro and in halting metastasis in pre-clinical models of breast cancer. We know that endothelial (blood vessel) cells that lack AQP1 are unable to form complete vascular networks. Procedures may include 3D cell culture, CRISPR gene knockout, RT-PCR, western blotting, functional cellbased assays and pre-clinical models of breast cancer.

To apply, or for more information please send your CV, academic transcripts and a ½ page expression of interest to This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

Applications close December 8th, 2017 for proposed start in March 2018.